1
Clinical Trials associated with Leish-111f + MPL-SE Vaccine(IDRI)A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India
The purpose of this study is to determine if a vaccine (called Leish-111f + MPL-SE) is safe and whether it can or cannot produce a protective response against visceral leishmaniasis when injected to healthy subjects.
100 Clinical Results associated with Leish-111f + MPL-SE Vaccine(IDRI)
100 Translational Medicine associated with Leish-111f + MPL-SE Vaccine(IDRI)
100 Patents (Medical) associated with Leish-111f + MPL-SE Vaccine(IDRI)
100 Deals associated with Leish-111f + MPL-SE Vaccine(IDRI)